BNTX BioNTech
- 89.950
- +1.130+1.27%
BioNTech News
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly lower Wednesday morning, declining 0.36% to 1,359.56 on the S&P Europe Select ADR Index. From continental Euro
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
WHO Picks JN.1 Variant for Next Set of COVID Vaccines
Express News | Pfizer and BioNTech Shares Are Trading Lower Amid Reports GSK Is Suing the Companies Alleging Patent Infringement Concerning MRNA Technology Used in Their COVID-19 Vaccines
Express News | Glaxosmithkline Sues Pfizer and BioNTech Over Mrna Technology Patents in Covid-19 Vaccines - US Court Filing
Scholz Promises Support for Pharma Sector in Germany as Merck Invests
BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.'
Pfizer Vs Moderna Battle Over COVID Vaccine Patents Begins in UK
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company
Assessing BioNTech: Insights From 11 Financial Analysts
Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table below ill
Express News | HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $107 Price Target
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Connect Biopharma Holdings (CNTB)
TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics
New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- TROP-2 Inhibitors Market to Boost by 2034, Predicts DelveInsight | Key Companies to Look Out - Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio,
BioNTech SE Virtual AGM Scheduled for May 2024
BioNTech Reports Positive 3-Year Data From Phase 1 Trial of Cevumeran in Pancreatic Cancer
BioNTech (BNTX) said Sunday that three-year follow-up data from a phase 1 trial on its immunotherapy candidate cevumeran in patients with resected pancreatic ductal adenocarcinoma, or PDAC, showed tha
Three-year Phase 1 Follow-Up Data for MRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients With Resected Pancreatic Cancer
BioNTech SE (Nasdaq: BNTX) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy ("iNeST") candidate autogene cevumeran (also known as BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma ("PDAC").
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher
European equities traded in the US as American depositary receipts kicked off the week slightly higher in late Monday morning trading, rising 0.11% to 1,375.19 on the S&P Europe Select ADR Index. From
Some Investors May Be Willing To Look Past BioNTech's (NASDAQ:BNTX) Soft Earnings
Soft earnings didn't appear to concern BioNTech SE's (NASDAQ:BNTX) shareholders over the last week.
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating
UBS Cuts BioNTech Price Target to $101 From $110, Maintains Neutral Rating.
Analysis
Price Target
No Data
